Table 1.
Peripheral CD3+CD56+ T cells and natural killer (NK) T cells in renal cell carcinoma patients of interferon (IFN)-α trial arms A and B
| Patient | % CD3+CD56+ | n† | % Vα24/Vβ11+ | n |
|---|---|---|---|---|
| A1‡ | 8·0 ± 4·1§ | 10 | 0·02 ± 0·02 | 12 |
| A2 | 0·7 ± 0·7 | 5 | 0·02 ± 0·01 | 5 |
| A3 | 3·1 ± 1·8 | 3 | 0·01 ± 0·00 | 4 |
| A4 | 6·9 ± 2·0 | 6 | 0·02 ± 0·03 | 6 |
| A5 | n.t. | 0·01 ± 0·01 | 2 | |
| A6 | 8·6 ± 4·9 | 2 | 0·32 ± 0·11 | 3 |
| B1 | 0·9 ± 0·1 | 2 | 0·04 ± 0·01 | 5 |
| B2 | 36·8 ± 9·3 | 4 | 1·65 ± 0·54¶ | 5 |
| B3 | 8·3 ± 2·2 | 4 | 0·05 ± 0·02 | 6 |
| B4 | 8·5 ± 3·3 | 4 | 0·01 ± 0·01 | 4 |
| B5 | 7·0 ± 4·1 | 3 | 0·14 ± 0·04 | 3 |
| B6 | 7·0 ± 2·6 | 2 | 0·00 ± 0·00 | 4 |
| B7 | 9·1 ± 5·8 | 3 | 7·64 ± 1·54¶ | 9 |
| B8 | 4·9 ± 2·6 | 2 | 0·13 ± 0·10 | 2 |
| Total without B2 and B7 | 0·06 ± 0·09 | 12 | ||
| Healthy donors | 5·1 ± 5·1 | 11 | 0·13 ± 0·15 | 14 |
†
Number of tests.
‡
Patients receiving IFN-α treatment after (A) or before and after (B) nephrectomy.
§
Mean percentage ± standard deviation of CD3+ T cells in peripheral blood mononuclear cells, calculated from all samples taken pre-, during and post-IFN-α therapy.
¶
Significantly different from healthy donor controls (P < 0·001)
n.t.: not tested.